网络药理学,分子动力学模拟和生物验证 洞察Ligustri Lucidi Fructus对糖尿病病的潜力
Manting Liu1, Yuhao Gu1, Yuchang Yang1
1School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102401, China.
International journal of molecular sciences
|July 12, 2025
概括
在治疗糖尿病病 (DN) 方面,Ligustri Lucidi Fructus (LLF) 通过向cGAS-STING通路显示出有前途. 这项研究确定了关键化合物和机制,验证了LLF的有效性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 传统中国医药 传统中国医药
- 分子生物学分子生物学
背景情况:
- 糖尿病病 (DN) 是糖尿病的一种严重并发症.
- 传统中医药中的一种Ligustri Lucidi Fructus (LLF) 具有抗DN作用.
- 在DN处理中LLF的精确机制和目标需要阐明.
研究的目的:
- 研究生物活性化合物,治疗点和LLF在DN治疗中的机制.
- 为了验证这些发现,使用一个体外模型的 podocyte 损伤.
- 为LLF在DN的临床应用提供科学基础.
主要方法:
- 网络药理学用于识别潜在的标和化合物.
- 为结合相互作用进行分子对接和动力学模拟.
- 使用棕酸诱导的MPC5 podocyte损伤模型进行生物验证.
主要成果:
- 确定了383个与DN相关的LLF目标,其中TNF是关键目标.
- 沙利德化物,阿皮基宁和酸显示出与TNF的潜在结合.
- 含有LLF的血清受体通过抑制cGAS-STING通路而受到保护.
结论:
- 通过化合物 - 目标 - 途径相互作用,LLF对DN产生性保护作用.
- cGAS-STING通路是LLF反DN活动中的关键机制.
- 这些发现支持对LLF用于DN治疗的进一步研究.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
663
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
184
相关概念视频
Ligand Binding Sites
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
